Trace Level Determination of p-Toluidine in Penem Drug Substances by Gas Chromatography
 
More details
Hide details
1
Aurobindo Pharma Limited Research Centre-II, Telangana, India
2
Andhra University College of Engineering, Andhra Predesh, India
CORRESPONDING AUTHOR
Siva K. Nachaka   

Aurobindo Pharma Limited Research Centre-II, Telangana, India
Publish date: 2017-10-27
 
Eurasian J Anal Chem 2016;11(2):89–99
KEYWORDS
ABSTRACT
A Gas chromatographic method using flame ionization detector (GC-FID) has been developed and validated for the quantitative determination of p-Toluidine in Meropenem trihydrate, Imipenem monohydrate, Doripenem monohydrate and Ertapenem monosodium pharmaceutical drug substances. The chromatographic method was achieved on fused silica capillary column (Rtx-5) with 5% diphenyl and 95% dimethyl polysiloxane stationary phase. The detection and quantitation limits obtained for p-Toluidine were 0.9 µg g-1 and 2.7 µg g-1 respectively. The relative standard deviation for analyte response was found as 0.9% for six replicate injections of standard equivalent to 100 µg g-1 of p-Toluidine. The average recoveries of p-Toluidine in Meropenem trihydrate, Imipenem monohydrate, Doripenem monohydrate and Ertapenem monosodium were obtained 99.6%, 99.2%, 96.7% and 107.9% respectively. The method was found to be linear in the range between 2.7 and 150 µg/g with a correlation coefficient 0.9999. The developed method was found to be robust for the determination of p-Toluidine in Penem drug substances.
 
REFERENCES (13)
1.
GoyalVK, Rajput SS (2014) Meropenem: Current perspective. International Journal of Medical Science Research and Practice; 1(1): 03-05.
 
2.
Takeuchi Y, Takebayashi Y, Sunagawa M, Isobe Y, Hamazume Y, Uemura A & Noguchi T (1993) The stability of a novel carbapenem antibiotic, meropenem (SM-7338), in a solid state formulation for injection. Chem Pharm Bull, 41: 1988-2002.
 
3.
John FM (2008) Update on the efficacy and tolerability of Meropenem in the treatment of serious bacterial infections. Clinical infectious Diseases, 47: S41-51.
 
4.
Martínez Lacasa J, Garau J. (1997) The role of carbapenems in the treatment of nosocomial infection Enferm Infect. Microbiol Clin, 15(1): 78-85.
 
5.
Baldwin CM, Lyseng-Williamson KA, Keam SJ (2008) Meropenem: a review of its use in the treatment of serious bacterial infections. Drugs, 68(6): 803-38.
 
6.
Park SY, Parker RH. (1986) Review of Imipenem. Infect Control, 7(6): 333-7.
 
7.
Clissold SP, Todd PA, Campoli-Richards DM. (1987) Imipenem/cilastatin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs, 33(3): 183-241.
 
8.
Raritan, NJ: Orth-McNeil. (2007) Doribax (doripenem for injection) [package insert]. Pharmaceutical Inc; http://www.doribax.com/doribax... pi.html.
 
9.
Matthews S J, Lancaster J W. (2009) Doripenem monohydrate, a broad-spectrum carbapenen antibiotic Database of Abstracts of Reviews of Effects (DARE): Qualityassessed Reviews. Clinical Therapeutics; 31(1): 42-63.
 
10.
Fiona Walsh (2007) Doripenem: A new carbapenem antibiotic a review of comparative antimicrobial and bactericidal activities. Ther Clin Risk Manag, 3(5): 789–794.
 
11.
Wexler HM. (2004) In vitro activity of ertapenem: review of recent studies. J Antimicrob Chemother, 53(2): 11-21.
 
12.
Falagas ME, Tansarli GS, Kapaskelis A, Vardakas KZ. (2013) Ertapenem use and antimicrobial resistance to group 2 carbapenems in Gram-negative infections: a systematic review. Expert Rev Anti Infect Ther, 11(1): 69-78. doi: 10.1586/eri.12.149.
 
13.
International Conference on Harmonization (ICH) (2005) of Technical requirements for registration of pharmaceuticals for human use, Topic Q2 (R1): Validation of Analytical procedure: Text and methodology, Geneva.
 
eISSN:1306-3057